The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How effective are JAK inhibitor combinations for patients with myelofibrosis?

During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Srdan Verstovsek, MD Anderson Cancer Center, Houston, US. We asked, How effective are JAK inhibitor combinations for patients with myelofibrosis?

How effective are JAK inhibitor combinations for patients with myelofibrosis?

JAK inhibitors can control progressive symptomatic splenomegaly and disease-related symptoms; however, they may also worsen anemia in patients with myelofibrosis. Verstovsek outlines JAK inhibitor combinations of luspatercept, CPI-0610, navitoclax, and hypomethylating agents to help manage a wider range of symptoms.

Share: